Catalent Inc (NYSE:CTLT)’s Stock Is Sell After More Market Selling

June 29, 2018 - By Susan Price

Catalent, Inc. (NYSE:CTLT) Logo

Investors sentiment decreased to 1.16 in 2018 Q1. Its down 0.28, from 1.44 in 2017Q4. It turned negative, as 23 investors sold Catalent, Inc. shares while 85 reduced holdings. 37 funds opened positions while 88 raised stakes. 127.42 million shares or 2.50% less from 130.69 million shares in 2017Q4 were reported.
Atria Limited Liability Company holds 0.01% of its portfolio in Catalent, Inc. (NYSE:CTLT) for 7,183 shares. Comerica Bancorporation invested in 0.03% or 105,991 shares. Proshare Limited Liability Corporation owns 31,806 shares for 0.01% of their portfolio. Barclays Public Limited Com accumulated 0% or 38,900 shares. Gsa Capital Ptnrs Ltd Liability Partnership invested 0.02% in Catalent, Inc. (NYSE:CTLT). Citigroup reported 0% stake. Moneta Gp Investment Advsrs Ltd Llc invested in 1,715 shares or 0.01% of the stock. New York-based Alliancebernstein Ltd Partnership has invested 0.01% in Catalent, Inc. (NYSE:CTLT). Texas Permanent School Fund owns 88,258 shares. Smith Asset Grp Lp owns 0.04% invested in Catalent, Inc. (NYSE:CTLT) for 26,310 shares. Brown Advisory has invested 0.21% in Catalent, Inc. (NYSE:CTLT). 260,552 are owned by California Pub Employees Retirement. Ing Groep Nv holds 0.02% or 20,279 shares in its portfolio. 597 are owned by Advisory Net Ltd Liability. Forward Mgmt Ltd holds 6,638 shares or 0.04% of its portfolio.

Since March 8, 2018, it had 0 insider buys, and 2 insider sales for $473,717 activity. Fasman Steven L sold $94,089 worth of stock.

The stock of Catalent Inc (NYSE:CTLT) registered an increase of 10.59% in short interest. CTLT’s total short interest was 3.19 million shares in June as published by FINRA. Its up 10.59% from 2.89M shares, reported previously. With 678,600 shares average volume, it will take short sellers 5 days to cover their CTLT’s short positions.

The stock increased 2.45% or $1.01 during the last trading session, reaching $42.27. About 336,167 shares traded. Catalent, Inc. (NYSE:CTLT) has risen 9.81% since June 29, 2017 and is uptrending. It has underperformed by 2.76% the S&P500.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. The company has market cap of $5.64 billion. It operates through three divisions: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. It has a 87.33 P/E ratio. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Catalent, Inc. (NYSE:CTLT) Ratings Coverage

Among 8 analysts covering Catalent (NYSE:CTLT), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Catalent has $50 highest and $44.0 lowest target. $47.20’s average target is 11.66% above currents $42.27 stock price. Catalent had 8 analyst reports since January 8, 2018 according to SRatingsIntel. Stephens downgraded the stock to “Hold” rating in Tuesday, February 6 report. The firm has “Buy” rating by Bank of America given on Tuesday, February 6. Jefferies maintained it with “Hold” rating and $44.0 target in Monday, February 5 report. Raymond James upgraded Catalent, Inc. (NYSE:CTLT) on Wednesday, March 21 to “Outperform” rating. The stock has “Buy” rating by RBC Capital Markets on Monday, February 5. The stock of Catalent, Inc. (NYSE:CTLT) has “Overweight” rating given on Wednesday, March 28 by KeyBanc Capital Markets.

Another recent and important Catalent, Inc. (NYSE:CTLT) news was published by Globenewswire.com which published an article titled: “Investor Expectations to Drive Momentum within AMC Entertainment, Arrowhead Pharmaceuticals, US Silica, Catalent …” on June 26, 2018.

Catalent, Inc. (NYSE:CTLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: